Bio-Giants Unite: Tsingke and iGeneTech Aim for Gene Synthesis Dominance

BEIJING – March 10, 2026 – In a significant move set to reshape the landscape of synthetic biology, two of China’s leading biotechnology firms, Tsingke Biotech and iGeneTech, have announced a strategic partnership. The collaboration, formalized at a ceremony in Beijing, aims to create a comprehensive and powerful platform for gene synthesis, combining their complementary strengths to accelerate innovation from digital design to real-world biological applications.

This alliance brings together Tsingke Biotech’s formidable, vertically integrated gene production capabilities with iGeneTech’s specialized high-throughput synthesis technology. The stated goal is to build an integrated system that spans the entire spectrum from “synthesis” to “application,” a move designed to meet the soaring demands of a global market hungry for faster, cheaper, and more reliable ways to engineer biology.

A New Era for Bio-Manufacturing

The core of the partnership lies in the powerful synergy between the two companies' technologies. Tsingke Biotech has established itself as a leader in gene synthesis through its “gene factory” model. This model is built on a fully integrated industrial chain that the company controls from end to end—from the raw chemical reagents and proprietary synthesis equipment to the AI-driven software that manages the entire production process. This gives Tsingke remarkable scalability, allowing it to produce synthetic DNA for everything from small-scale laboratory research (2nmol) to massive industrial applications (12mmol).

Into this large-scale production engine, iGeneTech injects its specialized expertise in high-throughput, high-precision synthesis. The company’s proprietary Ignite 3.0 platform is engineered to produce vast libraries of oligonucleotides, or “oligo pools.” These short strands of DNA are the fundamental building blocks for complex genetic research, particularly in gene editing. The Ignite 3.0 platform can generate pools of up to 650,000 unique oligos at a time, with lengths up to 200 nucleotides and an exceptionally low error rate of just 0.2%. This capability directly addresses the critical industry challenges of throughput, speed, and cost, which have often been bottlenecks for advanced research.

By combining Tsingke’s capacity for constructing long, complete genes with iGeneTech’s ability to rapidly produce massive quantities of precise DNA fragments, the partnership promises a streamlined workflow that was previously fragmented. Researchers and companies will be able to move more seamlessly from designing genetic circuits on a computer to testing them in the lab, drastically reducing development timelines for new therapies, improved crops, and novel biomaterials.

Powering Global Biotech Ambitions

This strategic alliance does not exist in a vacuum. It arrives as the global synthetic biology market is experiencing explosive growth. Valued at over $12 billion in 2024, the market is projected by industry analysts to expand at a compound annual growth rate (CAGR) of over 20%, potentially exceeding $31 billion by 2029. This growth is fueled by breakthroughs in DNA sequencing, a rising demand for sustainable bio-based products, and massive investment in fields like cell and gene therapy.

Within this global race, the Asia-Pacific region, with China at its forefront, is emerging as the fastest-growing hub. This partnership is a clear signal of China's ambition to move beyond being a consumer of biotechnology and become a key innovator and producer. By consolidating domestic expertise, Tsingke and iGeneTech are positioning themselves to compete directly with established Western biotech giants like Thermo Fisher Scientific, Agilent, and Merck.

The collaboration aims to create a national champion with the scale and technological sophistication to capture a significant share of the global market for DNA synthesis, which forms the foundational layer of the entire synthetic biology industry. “We are excited to partner with iGeneTech, whose expertise in gene capture and next-generation sequencing (NGS) technology enhances our strengths in gene synthesis,” said Mr. Shijin Ma, CEO of Tsingke Biotech. “This partnership will speed up the translation of technological innovations into real-world applications, helping drive the industry forward.”

From Synthesis to Breakthrough Applications

The ultimate measure of the partnership’s success will be its impact on science and society. The integrated platform is designed to be the engine for a new wave of innovation across multiple sectors. In medicine, the ability to rapidly and affordably synthesize vast DNA libraries is critical for developing next-generation precision therapies, including those based on the revolutionary CRISPR gene-editing tool. The creation of precise sgRNA libraries, a specialty of iGeneTech, is essential for identifying drug targets and developing safer, more effective treatments for genetic diseases.

In agriculture, synthetic biology offers the promise of “bio-breeding”—engineering crops that are more resilient to climate change, resistant to pests, and have higher nutritional value. The ability to design, build, and test thousands of genetic variations quickly can accelerate the development of these next-generation plants.

Mr. Wanshi Cai, CEO of iGeneTech, highlighted this focus on downstream impact, stating, “Tsingke Biotech's integrated industrial chain and leadership in gene synthesis will be crucial in supporting our continued growth. Together, we will push the boundaries of synthetic biology and its potential across various industries.”

Navigating a Complex Frontier

While the technological promise of the alliance is immense, the path forward is not without challenges. On a technical level, seamlessly integrating two distinct and complex manufacturing platforms will require significant engineering effort to harmonize software, hardware, and quality control protocols. Standardization remains a persistent challenge for the synthetic biology field as a whole, and ensuring consistent, reproducible results across the combined workflow will be critical for earning the trust of the scientific community.

Furthermore, as this powerful platform enables more advanced applications, it will invariably intersect with a complex and evolving regulatory and ethical landscape. The tools developed by the partnership will accelerate research in gene editing, a field that carries profound societal implications. While the companies are focused on providing research tools, the use of these tools in areas like human gene therapy is subject to strict oversight by regulatory bodies like the FDA in the United States and the EMA in Europe. The global scientific community continues to grapple with the ethical lines surrounding genetic modification, especially the highly controversial topic of heritable germline editing.

For now, the partnership between Tsingke Biotech and iGeneTech represents a powerful consolidation of industrial and technological might. It is a calculated move to build a dominant force in the foundational layer of the bio-economy, accelerating the journey of synthetic biology from a niche academic discipline to a transformative engine of 21st-century industry.